• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

7-氨基-[1,2,4]三唑并[1,5-a][1,3,5]三嗪类化合物作为 CK1δ 抑制剂:探索 2 位和 5 位取代基。

7-Amino-[1,2,4]triazolo[1,5-a][1,3,5]triazines as CK1δ inhibitors: Exploring substitutions at the 2 and 5-positions.

机构信息

Dipartimento di Scienze Chimiche e Farmaceutiche, Università degli Studi di Trieste, Via Licio Giorgieri 1, 34127 Trieste, Italy.

Molecular Modeling Section (MMS), Dipartimento di Scienze del Farmaco, Università di Padova, via Marzolo 5, 35131 Padova, Italy.

出版信息

Bioorg Chem. 2024 Oct;151:107659. doi: 10.1016/j.bioorg.2024.107659. Epub 2024 Jul 17.

DOI:10.1016/j.bioorg.2024.107659
PMID:39059072
Abstract

CK1δ is a serine-threonine kinase involved in several pathological conditions including neuroinflammation and neurodegenerative disorders like Alzheimer's disease, Parkinson's disease, and Amyotrophic Lateral Sclerosis. Specifically, it seems that an inhibition of CK1δ could have a neuroprotective effect in these conditions. Here, a series of [1,2,4]triazolo[1,5-a][1,3,5]triazines were developed as ATP-competitive CK1δ inhibitors. Both positions 2 and 5 have been explored leading to a total of ten compounds exhibiting ICs comprised between 29.1 µM and 2.08 µM. Three of the four most potent compounds (IC < 3 µM) bear a thiophene ring at the 2 position. All compounds have been submitted to computational studies that identified the chain composed of at least 2 atoms (e.g., nitrogen and carbon atoms) at the 5 position as crucial to determine a key bidentate hydrogen bond with Leu85 of CK1δ. Most potent compounds have been tested in vitro, resulting passively permeable to the blood-brain barrier and, safe and slight neuroprotective on a neuronal cell model. These results encourage to further structural optimize the series to obtain more potent CK1δ inhibitors as possible neuroprotective agents to be tested on models of the above-mentioned neurodegenerative diseases.

摘要

CK1δ 是一种丝氨酸-苏氨酸激酶,涉及多种病理状况,包括神经炎症和神经退行性疾病,如阿尔茨海默病、帕金森病和肌萎缩侧索硬化症。具体来说,似乎 CK1δ 的抑制可能对这些疾病具有神经保护作用。在这里,一系列 [1,2,4]三唑并[1,5-a][1,3,5]三嗪被开发为 ATP 竞争性 CK1δ 抑制剂。已经探索了位置 2 和 5,总共得到了 10 种具有 29.1 µM 和 2.08 µM 之间 IC 的化合物。四个最有效化合物中的三个(IC < 3 µM)在 2 位带有噻吩环。所有化合物都经过了计算研究,鉴定出由至少 2 个原子(例如氮原子和碳原子)组成的链在 5 位对于确定与 CK1δ 的 Leu85 的关键双齿氢键至关重要。最有效的化合物已在体外进行测试,结果表明它们对血脑屏障具有被动渗透性,并且在神经元细胞模型上具有安全性和轻微的神经保护作用。这些结果鼓励进一步对该系列进行结构优化,以获得更有效的 CK1δ 抑制剂,作为上述神经退行性疾病模型的潜在神经保护剂进行测试。

相似文献

1
7-Amino-[1,2,4]triazolo[1,5-a][1,3,5]triazines as CK1δ inhibitors: Exploring substitutions at the 2 and 5-positions.7-氨基-[1,2,4]三唑并[1,5-a][1,3,5]三嗪类化合物作为 CK1δ 抑制剂:探索 2 位和 5 位取代基。
Bioorg Chem. 2024 Oct;151:107659. doi: 10.1016/j.bioorg.2024.107659. Epub 2024 Jul 17.
2
Developing novel classes of protein kinase CK1δ inhibitors by fusing [1,2,4]triazole with different bicyclic heteroaromatic systems.通过将[1,2,4]三唑与不同的双环杂芳环系统融合,开发新型的蛋白激酶 CK1δ 抑制剂。
Eur J Med Chem. 2021 Apr 15;216:113331. doi: 10.1016/j.ejmech.2021.113331. Epub 2021 Mar 2.
3
A Triazolotriazine-Based Dual GSK-3β/CK-1δ Ligand as a Potential Neuroprotective Agent Presenting Two Different Mechanisms of Enzymatic Inhibition.基于三唑并三嗪的双重 GSK-3β/CK-1δ 配体,作为一种潜在的神经保护剂,呈现出两种不同的酶抑制机制。
ChemMedChem. 2019 Feb 5;14(3):310-314. doi: 10.1002/cmdc.201800778. Epub 2019 Jan 15.
4
Optimized 4,5-Diarylimidazoles as Potent/Selective Inhibitors of Protein Kinase CK1δ and Their Structural Relation to p38α MAPK.优化的4,5-二芳基咪唑作为蛋白激酶CK1δ的强效/选择性抑制剂及其与p38α丝裂原活化蛋白激酶的结构关系。
Molecules. 2017 Mar 24;22(4):522. doi: 10.3390/molecules22040522.
5
Synthesis and structure-activity relationships of 4-fluorophenyl-imidazole p38α MAPK, CK1δ and JAK2 kinase inhibitors.4-氟苯基咪唑p38α丝裂原活化蛋白激酶、细胞周期蛋白依赖性激酶1δ和Janus激酶2激酶抑制剂的合成及其构效关系
Bioorg Med Chem Lett. 2014 Aug 1;24(15):3412-8. doi: 10.1016/j.bmcl.2014.05.080. Epub 2014 Jun 2.
6
A Computational Workflow for the Identification of Novel Fragments Acting as Inhibitors of the Activity of Protein Kinase CK1δ.一种用于鉴定新型片段作为蛋白激酶 CK1δ 活性抑制剂的计算工作流程。
Int J Mol Sci. 2021 Sep 9;22(18):9741. doi: 10.3390/ijms22189741.
7
Casein Kinase 1δ Inhibitors as Promising Therapeutic Agents for Neurodegenerative Disorders.酪蛋白激酶 1δ 抑制剂作为神经退行性疾病有前景的治疗药物。
Curr Med Chem. 2022;29(27):4698-4737. doi: 10.2174/0929867329666220301115124.
8
Targeting Protein Kinase CK1δ with Riluzole: Could It Be One of the Possible Missing Bricks to Interpret Its Effect in the Treatment of ALS from a Molecular Point of View?以利鲁唑靶向蛋白激酶 CK1δ:从分子角度解释其在 ALS 治疗中作用的可能缺失环节之一?
ChemMedChem. 2018 Dec 20;13(24):2601-2605. doi: 10.1002/cmdc.201800632. Epub 2018 Nov 21.
9
Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.靶向VEGFR-2酶的新型三唑并[3,4-a]酞嗪衍生物的设计、合成、体外抗癌活性、ADMET特性及分子对接
Anticancer Agents Med Chem. 2018;18(8):1184-1196. doi: 10.2174/1871520618666180412123833.
10
Structural Investigations on 2-Amidobenzimidazole Derivatives as New Inhibitors of Protein Kinase CK1 Delta.2-氨基苯并咪唑衍生物作为蛋白激酶CK1δ新抑制剂的结构研究
Pharmaceuticals (Basel). 2024 Apr 7;17(4):468. doi: 10.3390/ph17040468.

引用本文的文献

1
In Vitro Activity of the Triazinyl Diazepine Compound FTSD2 Against Drug-Resistant Strains.三嗪基二氮杂䓬化合物FTSD2对耐药菌株的体外活性
Pharmaceuticals (Basel). 2025 Mar 2;18(3):360. doi: 10.3390/ph18030360.